{
    "clinical_study": {
        "@rank": "51877", 
        "arm_group": {
            "arm_group_label": "755nm Alexandrite Laser", 
            "arm_group_type": "Experimental", 
            "description": "755nm Alexandrite Laser"
        }, 
        "brief_summary": {
            "textblock": "Evaluate the safety and efficacy of removing unwanted scars using a 755nm Alexandrite laser."
        }, 
        "brief_title": "Evaluation of the 755nm Alexandrite Laser for the Treatment of Scars", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Scars", 
        "condition_browse": {
            "mesh_term": "Cicatrix"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Is a healthy male or female between 18 and 85 years old.\n\n          2. Has unwanted scars (including atrophic, hypertrophic, hyper or hypo pigmented,\n             erythematous )and wishes to undergo laser treatments to remove or improve them.\n\n          3. Is willing to consent to participate in the study.\n\n          4. Is willing to comply with all requirements of the study including being photographed,\n             following post treatment care and attending all treatment and follow up visits\n\n        Exclusion Criteria:\n\n          1. Is hypersensitive to light exposure.\n\n          2. Has active localized or systemic infection.\n\n          3. Is taking medication(s) for which sunlight is a contraindication.\n\n          4. Has a history of squamous cell carcinoma or melanoma.\n\n          5. Has a history of keloid scarring.\n\n          6. Has used oral isotretinoin (Accutane\u00ae) within 12 months of initial treatment or plans\n             on using during the course of the study. Note: Skin must regain its normal degree of\n             moisture prior to treatment.\n\n          7. Has a history of immunosuppression/immune deficiency disorders (including HIV\n             infection or AIDS) or use of immunosuppressive medications.\n\n          8. Is female and pregnant, has been pregnant within the last 3 months, is currently\n             breast feeding or planning a pregnancy during the study period.\n\n          9. Is allergic to lidocaine, tetracaine or Xylocaine with epinephrine.\n\n         10. Has any other reason determined by the physician to be ineligible to participate in\n             the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01811030", 
            "org_study_id": "CYN12-PICO_SCARS_RG06"
        }, 
        "intervention": {
            "arm_group_label": "755nm Alexandrite Laser", 
            "description": "755nm Alexandrite Laser", 
            "intervention_name": "755nm Alexandrite Laser", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10016"
                }, 
                "name": "Laser & Skin Surgery Center of New York"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "other_outcome": {
            "description": "histological evaluation of tissue samples pre-treatment and 3-4 months post treatment to assess safety and tolerability.", 
            "measure": "Subject biopsy sampling", 
            "safety_issue": "Yes", 
            "time_frame": "up to 4 months post treatment"
        }, 
        "overall_official": {
            "affiliation": "Cynosure, Inc.", 
            "last_name": "Patricia Krantz", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "2D and 3D photography", 
            "measure": "Photographic Evaluation of Scar Clearance", 
            "safety_issue": "No", 
            "time_frame": "up to 3 months post last treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01811030"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "4 months post last treatment"
        }, 
        "source": "Cynosure, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cynosure, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}